COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,189 Articles (22,713 medRxiv, 8,476 bioRxiv)

Most recent first Previous |  Page 1141: Articles 11401-11410  | Next

Severity and inpatient mortality of COVID-19 pneumonia from Beta variant infection: a clinical cohort study in Cape Town, South Africa
Boloko, L., Lifson, A., Little, F., De Wet, T., Papavarnavas, N., Marais, G., Hsiao, N.-y., Roslee, M.-J., Doolabh, D., Iranzadeh, A., Williamson, C., Dlamini, S., Mendelson, M., Ntusi, N., Wilkinson, R., Hussey, H., Davies, M.-A., Meintjes, G., Wasserman, S.
10.1101/2021.11.04.21265916 — Posted: 2021-11-04
SARS-CoV-2 Aerosol Transmission Indoors: A Closer Look at Viral Load, Infectivity, the Effectiveness of Preventive Measures and a Simple Approach for Practical Recommendations
Kriegel, M., Hartmann, A., Buchholz, U., Seifried, J., Baumgarte, S., Gastmeier, P.
10.1101/2021.11.04.21265910 — Posted: 2021-11-04
Estimation of the basic reproduction number of COVID-19 from the incubation period distribution
Basnarkov, L., Tomovski, I., Avram, F.
10.1101/2021.11.04.21265937 — Posted: 2021-11-04
Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccines in healthy adults
Wanlapakorn, N., Suntronwong, N., Phowatthanasathian, H., Yorsaeng, R., Vichaiwattana, P., Thongmee, T., Auphimai, C., Srimuan, D., Thatsanatorn, T., Assawakosri, S., Kanokudom, S., Poovorawan, Y.
10.1101/2021.11.04.21265908 — Posted: 2021-11-04
Ultrapotent and Broad Neutralization of SARS-CoV-2 Variants by Modular, Tetravalent, Bi-paratopic Antibodies
Miersch, S., Saberianfar, R., Chen, C., Sharma, N., Amarasinghe, G. K., Caruso, A., Caccuri, F., Zani, A., Novelli, G., Sidhu, S. S.
10.1101/2021.11.02.466984 — Posted: 2021-11-04
Coronavirus RNA synthesis takes place within membrane-bound sites
Doyle, N., Simpson, J., Hawes, P. C., Maier, H. J.
10.1101/2021.11.04.467246 — Posted: 2021-11-04
Marked enhancement of neutralizing antibody and IFN-γ T-cell responses by GX-19N DNA booster in mice primed with inactivated vaccine
Seo, Y. B., Shin, D., Suh, Y. S., Na, J., Ryu, J. I., Sung, Y. C.
10.1101/2021.11.02.467026 — Posted: 2021-11-04
Comparing protein-protein interaction networks of SARS-CoV-2 and (H1N1) influenza using topological features
Khojasteh, H., Khanteymoori, A., Olyaee, M. H.
10.1101/2021.11.02.463717 — Posted: 2021-11-04
Protein arginylation is regulated during SARS-CoV-2 infection
Macedo-da-Silva, J., Rosa-Fernandes, L., Gomes, V. d. M., Santiago, V. F., Molnar, C. M. S., Barboza, B. R., de Sousa, E. E., Durigon, E. L., Marinho, C. R. F., Wrenger, C., Marie, S. K. N., Palmisano, G.
10.1101/2021.11.02.466971 — Posted: 2021-11-04 Discussion: Offsite
Clinically observed deletions in SARS-CoV-2 Nsp1 affect protein stability and its ability to inhibit translation
Kumar, P., Schexnaydre, E., Rafie, K., Terenin, I., Hauryliuk, V., Carlson, L.-A.
10.1101/2021.11.03.467065 — Posted: 2021-11-04

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).